Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Hadasit Medical Research Services and Development Ltd.

Other

Institut National De La Sante Et De La Recherche Medicale

Fox Chase Cancer Center

Enzo Therapeutics, Inc.

Arie Dagan

Shimon Gatt

Shimon Slavin

Itamar Willner

Yael Cohen

Yechezkel Barenholz

Yaron Ilan

Saul Yedgar

Shmuel A Ben-Sasson

Meir Bialer

Rivka Cohen

Eugenii Katz

Ron Blonder

Rene Santus

Azalia Riklin

Danielle Hirsch-Lerner

Jeremy Zahavi

Shlomo Levi

Jeremy Zahavy

Sharon Perles

Sussan Sherbel

J Donald Chapman

Jean-Claude Maziere

Edward L Engelhardt

Shai Rubin

Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith.

Tricyclic compounds, compositions comprising them and uses thereof

The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

Synthetic analogs of sphingolipids

The invention relates to novel synthetic derivatives of &#x3b2;-glycolipids and uses thereof as immunomodulators. More particularly, the invention relates to synthetic derivatives of &#x3b2;-glycolipids, specifically, the compounds of any one of Formula I, II III and IV or any mixture or combination thereof, and particularly the ALIB-97 (Formula II) derivative and uses thereof for the treatment of different pathologic disorders, particularly, immune-related hepatic disorders and pathologies associated with the metabolic syndrome.

Synthetic derivatives beta glycolipids and compositions thereof for the treatment of pathologic disorders

The extent of binding of a moiety, such as a biomolecule, to a surface, where the local environment at the surface has a pH or surface potential which is altered upon binding of the moiety, is determined by stably incorporating at the surface a probe which contains a pH- or potential-sensitive fluorophore.

Detection of binding of charged species using PH- or potential-sensitive probes

Binding between two members of a recognition pair, e.g. antigen-antibody is determined by utilizing a probe which includes a piezoelectric crystal with electrodes on two opposite faces of the crystal. The crystal carries one or more metal plates which may be the same or different than the electrodes, the metal plates having immobilized thereon a first member of a recognition pair. Binding of a second member of the recognition pair to the first member, or dissociation between the two members and release of the second member from the probe, causes a change of immobilized mass which results in a change to the probe's resonance frequency. The immobilized members may be immobilized on the surface of the metal plates by means of a linking group, having the following general formula (I): Z&mdash;R &mdash;Q, wherein Z represents a sulphur-containing moiety which is capable of chemical association with, attachment to or chemisorption onto the metal, R represents a connecting group, Q is a functional group which is capable of forming a covalent bond with a moiety of said first member of the recognition pair.

Determination of an analyte in a liquid medium

According to the present invention, anticonvulsant compounds N-acetyl,N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide are disclosed. The present invention also discloses an anticonvulsant pharmaceutical composition comprising an effective amount of at least one active ingredient selected from N-acetyl,N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide and a pharmaceutically acceptable carrier or diluent. The present invention provides a method of controlling convulsions in a mammal by administering to the mammal an effective amount of antiepileptic compounds N-acetyl,N'-benzylglycinamide or N-benzyloxycarbonylglycinamide-Z-glycinamide. Combinations of the anticonvulsion compounds can also be administered. The convulsions may be due to epilepsy, febrile convulsions or convulsions precipitated by irritative lesions in the brain. Further the composition may be used to prevent migraine and to treat chronic pain and bipolar disorder.

Anticonvulsant drugs and pharmaceutical compositions thereof

An elcctrobiochemical system for the determination of the presence and optionally concentration of an analyte in a liquid medium, the system comprising an electrode having immobilized thereon a member of a recognition pair, the other member of said pair being said analyte, the presence of said analyte in the medium resulting in formation of a pair complex, being a complex between said immobilized member and said analyte; the system further comprising redox molecules capable of changing their redox state by accepting electrons from or donating electrons to the electrode; the formation of the pair complex on the electrode bringing a change in the electrical response of the system, whereby the presence and optionally the concentration of said analyte in the medium can be determined.

Electrobiochemical method and system for the determination of an analyte

Phorbine derivatives having high potency and light absorptivity in the 650 to 780 nanometer range are useful in cancer diagnosis and therapy, especially photodynamic therapy.

Phorbine derivatives and their use in the diagnosis and therapy of cancer

Inhibitors of phospholipase A.sub.2 activity at the cell-surface membrane whose molecular structure comprises a cell-permeable PLA.sub.2 -inhibitor moiety covalently bonded directly or indirectly to a physiologically acceptable carrier moiety which is effective to inhibit cell internalization of the cell-permeable PLA.sub.2 -inhibitor moiety, with the proviso that phosphatidylserine is not bonded indirectly via divalent dodecanedioyl to dextrane hydrazide.

Phospholipase A.sub.2 inhibiting compositions and their use

Growing community of inventors

Jerusalem, Israel

Arie Dagan